Information on the rare disease hereditary angioedema (HAE), its symptoms and treatment options is now available in five major languages on www.HAE-Network.info. The international internet web site offers doctors in-depth information on HAE, including scientific literature, conference calendar, reviews, all available contact data of HAE expert centers throughout Europe, consensus documents and case reports.
Via a database service, physicians can access relevant papers as PDF-documents direct through the publishers' web site. In addition, medical specialists can exchange know-how and experience by logging into the site's multimedia learning sessions or by joining specialised forums. The international portal is available in English, French, German, Italian and Spanish.
The web site is sponsored and maintained by Berlin, Germany-based Jerini AG, which is developing the HAE treatment icatibant, for which it has recently applied for US and European marketing approvals (Marketletters passim).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze